Current Progress in the Clinical Management and Basic Science of Head and Neck Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 20 April 2025 | Viewed by 931
Special Issue Editor
Interests: head and neck cancer; immunotherapy; chemoradiotherapy; surgery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Every year, more than 800,000 patients are newly diagnosed with HNSCC worldwide and 450,000 patients with HNSCC die. Cigarette smoking, alcohol consumption, and viral infections are recognized as they major factors that can cause HNSCC. In addition to surgery and chemoradiotherapy, molecule-targeted therapy and immunotherapy are the main treatment options for HNSCC. As this area of basic and clinical research has rapidly progressed in recent years, it is important that clinicians understand the basic biology of HNSCC so that they are able to choose an appropriate therapy in the upcoming era of personalized medicine. In this Special Issue of Cancers, we welcome both original research and reviews regarding clinical advances in the treatment of HNSCC as well as basic research on its carcinogenesis, the tumor microenvironment and microbiome, and antitumor immunity. Reports of clinical experience or case series are also acceptable if they are related to particularly interesting topics within the field.
Dr. Takumi Kumai
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- head and neck cancer
- immunotherapy
- chemoradiotherapy
- surgery
- molecular biology
- oncogenesis
- cancer immunology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.